Relieves muscle spasm associated with acute, painful musculoskeletal conditions. ANDA 77797, held by Prinston Pharmaceutical. Cyclobenzaprine Hydrochloride.
As of Nov 18, 2026, ANDA 77797 (Cyclobenzaprine Hydrochloride), held by Prinston Pharmaceutical, was first approved by FDA on Feb 28, 2007, with 3 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Cyclobenzaprine hydrochloride tablets are indicated as an adjunct to rest and physical therapy for relief of muscle spasm associated with acute, painful musculoskeletal conditions. Improvement is manifested by relief of muscle spasm and its associated signs and symptoms, namely, pain, tenderness, limitation of motion, and restriction in activities of daily living.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Feb 28, 2007 | Original application | Approved | None posted |
| Cyclobenzaprine Hydrochloride5MG · tablet;oral | Cyclobenzaprine Hydrochloride | Rx |
| Cyclobenzaprine Hydrochloride10MG · tablet;oral | Cyclobenzaprine Hydrochloride | Rx |
| Apr 11, 2013 | Supplement 10Labeling · Standard review | Approved | None posted |
| Jan 6, 2009 | Supplement 4Labeling | Approved | None posted |
| Aug 7, 2008 | Supplement 2Labeling | Approved | None posted |
| Feb 28, 2007 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters